Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15719397 | 1.00 | ALDH1A1 (0.41) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL6907966 | 0.81 | ALDH1A1 (0.44) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL9133975 | 0.81 | ALDH1A1 (0.44) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL6907971 | 0.81 | ALDH1A1 (0.44) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL9618602 | 0.81 | ALDH1A1 (0.44) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL17679183 | 0.80 | — | — | |
| SCHEMBL9133960 | 0.78 | ALDH1A1 (0.41) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL23165485 | 0.75 | ALDH1A1 (0.45) | ALDH1A1EPHX1SPHK1SPHK2 | |
| SCHEMBL8968579 | 0.74 | ALDH1A1 (0.43) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL13441848 | 0.74 | ALDH1A1 (0.48) | ALDH1A1EPHX1TSHRTHRBSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102067-A1 | OXIRAN AMINES | V-BIOTEK HOLDING APS (DK) | 2016-04-14 | — | — | US | disclosed |
| US-20160102067-A1 | OXIRAN AMINES | V-BIOTEK HOLDING APS (DK) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102067-A1 | OXIRAN AMINES | OXGR1, OTC, OXTR | ALDH1A1 571/4885EPHX1 150/4885TSHR 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.